Clinical trials: Newly Diagnosed Mantle Cell Lymphoma, open to volunteers
Lymphoma, Mantle-Cell, Lymphoma, Non-Hodgkin
This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma
This is a phase II, open-label, multicentre study of Zanubrutinib-containing regimens in patients with newly diagnosed mantle cell lymphoma.
- Trial name
- NCT06427213
- Testing
- Zanubrutinib,Obinutuzumab, Zanubrutinib and R-BAC
- Volunteers
- 41 people
- Sponsor
- Henan Cancer Hospital
Mantle Cell Lymphoma
A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma
This is a phase 2, multicenter, open-label, active-controlled randomized trial to determine efficacy and safety of rituximab/bendamustine (RB) alternating with rituximab/bendamustine/cytarabine (RBAC) compared with standard RB…
- Trial name
- NCT05245656
- Testing
- RB/RBAC alternating, RB
- Where
- South Korea
- Volunteers
- 90 people
- Sponsor
- Kim, Seok Jin
Mantle Cell Lymphoma
A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients
Evaluation the efficacy and safety of Zanubrutinib + R-CHOP/R-DHAP for the treatment mantle cell lymphoma.
- Trial name
- Z+RCHOP/RDHAP (NCT06255704)
- Testing
- Zanubrutinib and RCHOP/RDHAP
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Shanxi Province Cancer Hospital
Newly Diagnosed Mantle Cell Lymphoma
A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma
An open-label, single-arm, multicenter, prospective clinical study of Hanlikang and BTK inhibitors in the treatment of newly diagnosed mantle cell lymphoma
- Trial name
- NCT05506410
- Testing
- Rituximab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhengzhou University
Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
This phase I/II trial tests the safety and effectiveness of glofitamab (with obinutuzumab pretreatment), venetoclax, and lenalidomide in treating patients with newly diagnosed, high risk mantle cell lymphoma.
- Conditions
- Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma
- Trial name
- NCT05861050
- Testing
- Biopsy, Biospecimen Collection, Bone Marrow Biopsy
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- City of Hope Medical Center
Lymphoma, Mantle-Cell
A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of Zanubrutinib given in combination with bendamustine and rituximab in (elderly or TP53 alterations or chemotherapy intolerance) patients with newly diagnosed…
- Trial name
- NCT06136351
- Testing
- Zanubrutinib, Rituximab, Bendamustin
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Ruijin Hospital
Intermediate-to-High-Risk Mantle Cell Lymphoma, the Efficacy and Safety
The Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL
A Single-Arm, Prospective Clinical Study Evaluating the Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined with Obinutuzumab in the First-Line Treatment of Newly Diagnosed Intermediate-to-High-Risk Mantle Cell Lymphoma
- Trial name
- NCT07548255
- Testing
- Sonrotoclax, Zanubrutinib Combined with Obinutuzumab
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Ruijin Hospital